Development of an MRI Radiomic Machine-Learning Model to Predict Triple-Negative Breast Cancer Based on Fibroglandular Tissue of the Contralateral Unaffected Breast in Breast Cancer Patients

被引:0
|
作者
Lo Gullo, Roberto [1 ,2 ]
Ochoa-Albiztegui, Rosa Elena [2 ]
Chakraborty, Jayasree [3 ]
Thakur, Sunitha B. [2 ,4 ]
Robson, Mark [5 ]
Jochelson, Maxine S. [2 ]
Varela, Keitha [6 ]
Resch, Daphne [7 ]
Eskreis-Winkler, Sarah [2 ]
Pinker, Katja [1 ,2 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, Irving Med Ctr, Dept Radiol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[6] CUNY, Sch Med, New York, NY 10031 USA
[7] Sigmund Freud Univ, Med Sch, A-1020 Vienna, Austria
关键词
breast cancer; triple-negative breast cancer; radiomics; fibroglandular tissue; SUBTYPES; PATTERNS;
D O I
10.3390/cancers16203480
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Triple-negative breast cancer is the most aggressive breast cancer subtype. However, women at risk for developing triple-negative breast cancer may not be identified by existing risk models. Thus, we present a study to determine if triple-negative breast cancer can be predicted based on a radiomic analysis and the machine-learning features of the fibroglandular tissue of the contralateral unaffected breast. Our initial results indicate that this approach can be used to predict triple-negative breast cancer. In the future, triple-negative breast-cancer-specific models may be implemented in the screening workflow to identify those women who are at elevated risk for triple-negative breast cancer specifically, for whom early detection and treatment are most essential.Abstract Aim: The purpose of this study was to develop a radiomic-based machine-learning model to predict triple-negative breast cancer (TNBC) based on the contralateral unaffected breast's fibroglandular tissue (FGT) in breast cancer patients. Materials and methods: This study retrospectively included 541 patients (mean age, 51 years; range, 26-82) who underwent a screening breast MRI between November 2016 and September 2018 and who were subsequently diagnosed with biopsy-confirmed, treatment-na & iuml;ve breast cancer. Patients were divided into training (n = 250) and validation (n = 291) sets. In the training set, 132 radiomic features were extracted using the open-source CERR platform. Following feature selection, the final prediction model was created, based on a support vector machine with a polynomial kernel of order 2. Results: In the validation set, the final prediction model, which included four radiomic features, achieved an F1 score of 0.66, an area under the curve of 0.71, a sensitivity of 54% [47-60%], a specificity of 74% [65-84%], a positive predictive value of 84% [78-90%], and a negative predictive value of 39% [31-47%]. Conclusions: TNBC can be predicted based on radiomic features extracted from the FGT of the contralateral unaffected breast of patients, suggesting the potential for risk prediction specific to TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Pembrolizumab in Triple-Negative Breast Cancer
    Altundag, Kadri
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (15): : 1435 - 1436
  • [42] A Review of Triple-Negative Breast Cancer
    Ismail-Khan, Roohi
    Bui, Marilyn M.
    CANCER CONTROL, 2010, 17 (03) : 173 - 176
  • [43] Triple-negative breast cancer: an update
    Boolbol, Susan K.
    Cate, Sarah P.
    BREAST CANCER MANAGEMENT, 2014, 3 (02) : 127 - 129
  • [44] Morphotypes of the triple-negative breast cancer
    Koleckova, M.
    Kolar, Z.
    Ehrmann, J.
    Korinkova, G.
    Trojanec, R.
    VIRCHOWS ARCHIV, 2017, 471 : S296 - S296
  • [45] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [46] Targeting triple-negative breast cancer
    Kirkpatrick, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 21 - 21
  • [47] Pathogenesis of Triple-Negative Breast Cancer
    Derakhshan, Fatemeh
    Reis-Filho, Jorge S.
    ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2022, 17 : 181 - 204
  • [48] Imaging of triple-negative breast cancer
    Dogan, B. E.
    Turnbull, L. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 23 - 29
  • [49] Chemoimmunotherapy for Triple-Negative Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (24): : 2521 - 2521
  • [50] Pembrolizumab for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2020, 21 (04): : E183 - E183